share_log

Stifel Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $45

Stifel Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $45

Stifel 以購買評級啟動礦物質治療藥物的覆蓋範圍,宣布目標價格為 45 美元
Benzinga ·  2023/03/07 05:21

Stifel analyst Annabel Samimy initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $45.

Stifel分析師Annabel Samimy以買入評級啟動對Mineralys治療公司(納斯達克:MLYS)的報道,並宣佈目標價為45美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論